Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 11/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6451311 | 0.87 | SYK (0.40) | HSD11B1LRRK2CAPN1 | |
| SCHEMBL6449840 | 0.82 | PTGER1 (0.44) | PTGER1HSD11B1CCR5ALDH1A1HTT | |
| SCHEMBL6454384 | 0.81 | CCR5 (0.46) | PTGER1CCR5ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL6449993 | 0.79 | EPHX2 (0.36) | HSD11B1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6452335 | 0.73 | GABRA1 (0.41) | HSD11B1ALDH1A1HTTCYP2C9CYP1A2 | |
| SCHEMBL28286296 | 0.73 | CCR5 (0.55) | PTGER1CCR5ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL30835001 | 0.73 | CCR5 (0.55) | PTGER1CCR5ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL6449976 | 0.72 | EPHX2 (0.41) | HSD11B1HTTCYP1A2CAPN1 | |
| SCHEMBL3726426 | 0.71 | PTGER1 (0.54) | PTGER1CCR5ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL30955958 | 0.71 | PTGER1 (0.54) | PTGER1CCR5ALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | PTGER1 3096/4885HSD11B1 357/4885CCR5 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.